Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Dec 8, 2025 · Filed Dec 8, 2025
Edwards Lifesciences's CVP, JAPAC sold $50K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$50,144
Shares × reported transaction price
39 days after results of Oct 30, 2025, 64 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $84.32 on Dec 8, 2025, within 3% of its 52-week high, after an 11% rise over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $86.82 (Nov 25, 2025), 87% of the way up, from 250 adjusted closes. 30 trading days earlier: $76.10 on Oct 24, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
FDA approved SAPIEN M3 Transcatheter Mitral Valve Replacement System on Dec 22, 2025, 14 days after this trade.
Premarket approval (PMA): Prosthesis, mitral valve, percutaneously delivered. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.5% | -0.6% | +3.1% |
| 30 days | +1.6% | +0.9% | +0.6% |
| 90 days | +1.2% | -0.7% | +1.9% |
| 180 days | +3.1% | +8.2% | -5.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$223K of Edwards Lifesciences
Scheduled in advanceOfficer sold ~$749K of Edwards Lifesciences
Scheduled in advance
